Healthcare Policy Lobbyist (Biotech)

About The Initiative

The Clinical Trial Abundance Initiative exists to reform the federal policy and law governing clinical trials, making them faster, cheaper, and simpler to conduct. Founded by a coalition of leading science philanthropies, the initiative aims to leverage the 2027 reauthorization of the Prescription Drug User Fee Act (PDUFA) to enact real reform and sustain momentum beyond it.

We draw on successful international models, such as Australia's notification-based trial pathway and reforms across the UK and elsewhere, to inform our efforts.

What This Role Is — And Isn't

This is a policy and law reform role, not an operations or access role. The work involves changing the rules governing clinical trials to enable more trials to be launched, run, and approved faster and at lower cost. You will not be operating or running trials, nor will the role focus on trial access, diversity, inclusion, or equity.

The role exists to make trials themselves faster, cheaper, and more abundant to conduct by reforming the system that governs them. It is a founding leadership role, working closely with the initiative's Chief Science Officer to build the effort from the ground up.

The role runs on two horizons at once. In the near term, you are the initiative's credible face in policy, shaping the legislative and regulatory reform agenda and driving it into the PDUFA 2027 window and its implementation. Over the medium term, you build the field by creating a durable, formidable coalition of companies, investors, researchers, patient organizations, and policymakers who will carry this work long after any single legislative moment.

What You'll Do

• Serve as the initiative's lead voice with legislators, congressional staff, and agency officials, and with health-system and industry leaders—building credibility and trust across a wide and varied set of stakeholders.
• Shape a substantive agenda to reform the policy and law around the cost, speed, and complexity of trials, and drive it into the PDUFA 2027 reauthorization and its implementation.
• Design and build the coalition—recruiting and aligning companies, investors, research and patient organizations, and allied policymakers into a lasting interest group.
• Translate the scientific and regulatory case for reform into arguments that move different audiences, in partnership with the Chief Science Officer.
• Set the initiative's strategy for the years beyond 2027, when the work is field-building rather than chasing a single deadline.

Requirements

• Deep credibility in biotech, life sciences, or FDA/clinical-trial policy—this is a subject-matter role, not a generalist government-affairs one.
• A track record of being taken seriously by senior, varied stakeholders: Hill offices, agencies, industry executives, investors, and researchers alike.
• Evidence that you can build something durable, not just win a near-term legislative fight—coalition-building, institution-building, or genuine 0→1 experience.
• Fluent in the case for reform that expands what's possible—cutting the friction, cost, and time between good science and the patients who need it.

Nice to Have

• Direct experience with PDUFA, user-fee reauthorizations, or FDA review-pathway reform.
• Familiarity with international regulatory models (Australia, UK, EU).
• An existing network spanning biotech, investors, research, and DC policy.

Benefits

• Competitive salary of $200,000 - $250,000 USD/year.
• Private Health Insurance.
• Paid Time Off.
• Work From Home.
• Training & Development.